Literature DB >> 34166836

Biomarker Risk Score Algorithm and Preoperative Stratification of Patients with Pancreatic Cystic Lesions.

Michele T Yip-Schneider1, Huangbing Wu2, Hannah R Allison3, Jeffrey J Easler4, Stuart Sherman4, Mohammad A Al-Haddad5, John M Dewitt4, C Max Schmidt6.   

Abstract

BACKGROUND: Pancreatic cysts are incidentally detected in up to 13% of patients undergoing radiographic imaging. Of the most frequently encountered types, mucin-producing (mucinous) pancreatic cystic lesions may develop into pancreatic cancer, while nonmucinous ones have little or no malignant potential. Accurate preoperative diagnosis is critical for optimal management, but has been difficult to achieve, resulting in unnecessary major surgery. Here, we aim to develop an algorithm based on biomarker risk scores to improve risk stratification. STUDY
DESIGN: Patients undergoing surgery and/or surveillance for a pancreatic cystic lesion, with diagnostic imaging and banked pancreatic cyst fluid, were enrolled in the study after informed consent (n = 163 surgical, 67 surveillance). Cyst fluid biomarkers with high specificity for distinguishing nonmucinous from mucinous pancreatic cysts (vascular endothelial growth factor [VEGF], glucose, carcinoembryonic antigen [CEA], amylase, cytology, and DNA mutation) were selected. Biomarker risk scores were used to design an algorithm to predict preoperative diagnosis. Performance was tested using surgical (retrospective) and surveillance (prospective) cohorts.
RESULTS: In the surgical cohort, the biomarker algorithm outperformed the preoperative clinical diagnosis in correctly predicting the final pathologic diagnosis (91% vs 73%; p < 0.000001). Specifically, nonmucinous serous cystic neoplasms (SCN) and mucinous cystic neoplasms (MCN) were correctly classified more frequently by the algorithm than clinical diagnosis (96% vs 30%; p < 0.000008 and 92% vs 69%; p = 0.04, respectively). In the surveillance cohort, the algorithm predicted a preoperative diagnosis with high confidence based on a high biomarker score and/or consistency with imaging from ≥1 follow-up visits.
CONCLUSIONS: A biomarker risk score-based algorithm was able to correctly classify pancreatic cysts preoperatively. Importantly, this tool may improve initial and dynamic risk stratification, reducing overdiagnosis and underdiagnosis.
Copyright © 2021 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34166836      PMCID: PMC8403144          DOI: 10.1016/j.jamcollsurg.2021.05.030

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.532


  29 in total

Review 1.  Diagnosis and management of cystic lesions of the pancreas.

Authors:  William R Brugge
Journal:  J Gastrointest Oncol       Date:  2015-08

Review 2.  Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis.

Authors:  Laurens A van der Waaij; Hendrik M van Dullemen; Robert J Porte
Journal:  Gastrointest Endosc       Date:  2005-09       Impact factor: 9.427

3.  Systematic review and meta-analysis: Prevalence of incidentally detected pancreatic cystic lesions in asymptomatic individuals.

Authors:  Giulia Zerboni; Marianna Signoretti; Stefano Crippa; Massimo Falconi; Paolo Giorgio Arcidiacono; Gabriele Capurso
Journal:  Pancreatology       Date:  2018-11-28       Impact factor: 3.996

4.  Surgical overtreatment of pancreatic intraductal papillary mucinous neoplasms: Do the 2017 International Consensus Guidelines improve clinical decision making?

Authors:  Jeremy M Sharib; Annabelle L Fonseca; Douglas S Swords; Katrin Jaradeh; Paige M Bracci; Matthew A Firpo; Stacy Hatcher; Courtney L Scaife; Huamin Wang; Grace E Kim; Sean J Mulvihill; Anirban Maitra; Eugene J Koay; Kimberly S Kirkwood
Journal:  Surgery       Date:  2018-08-28       Impact factor: 3.982

5.  A multimodality test to guide the management of patients with a pancreatic cyst.

Authors:  Simeon Springer; David L Masica; Marco Dal Molin; Christopher Douville; Christopher J Thoburn; Bahman Afsari; Lu Li; Joshua D Cohen; Elizabeth Thompson; Peter J Allen; David S Klimstra; Mark A Schattner; C Max Schmidt; Michele Yip-Schneider; Rachel E Simpson; Carlos Fernandez-Del Castillo; Mari Mino-Kenudson; William Brugge; Randall E Brand; Aatur D Singhi; Aldo Scarpa; Rita Lawlor; Roberto Salvia; Giuseppe Zamboni; Seung-Mo Hong; Dae Wook Hwang; Jin-Young Jang; Wooil Kwon; Niall Swan; Justin Geoghegan; Massimo Falconi; Stefano Crippa; Claudio Doglioni; Jorge Paulino; Richard D Schulick; Barish H Edil; Walter Park; Shinichi Yachida; Susumu Hijioka; Jeanin van Hooft; Jin He; Matthew J Weiss; Richard Burkhart; Martin Makary; Marcia I Canto; Michael G Goggins; Janine Ptak; Lisa Dobbyn; Joy Schaefer; Natalie Sillman; Maria Popoli; Alison P Klein; Cristian Tomasetti; Rachel Karchin; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Christopher L Wolfgang; Ralph H Hruban; Anne Marie Lennon
Journal:  Sci Transl Med       Date:  2019-07-17       Impact factor: 17.956

6.  A combination of molecular markers and clinical features improve the classification of pancreatic cysts.

Authors:  Simeon Springer; Yuxuan Wang; Marco Dal Molin; David L Masica; Yuchen Jiao; Isaac Kinde; Amanda Blackford; Siva P Raman; Christopher L Wolfgang; Tyler Tomita; Noushin Niknafs; Christopher Douville; Janine Ptak; Lisa Dobbyn; Peter J Allen; David S Klimstra; Mark A Schattner; C Max Schmidt; Michele Yip-Schneider; Oscar W Cummings; Randall E Brand; Herbert J Zeh; Aatur D Singhi; Aldo Scarpa; Roberto Salvia; Giuseppe Malleo; Giuseppe Zamboni; Massimo Falconi; Jin-Young Jang; Sun-Whe Kim; Wooil Kwon; Seung-Mo Hong; Ki-Byung Song; Song Cheol Kim; Niall Swan; Jean Murphy; Justin Geoghegan; William Brugge; Carlos Fernandez-Del Castillo; Mari Mino-Kenudson; Richard Schulick; Barish H Edil; Volkan Adsay; Jorge Paulino; Jeanin van Hooft; Shinichi Yachida; Satoshi Nara; Nobuyoshi Hiraoka; Kenji Yamao; Susuma Hijioka; Schalk van der Merwe; Michael Goggins; Marcia Irene Canto; Nita Ahuja; Kenzo Hirose; Martin Makary; Matthew J Weiss; John Cameron; Meredith Pittman; James R Eshleman; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Rachel Karchin; Ralph H Hruban; Bert Vogelstein; Anne Marie Lennon
Journal:  Gastroenterology       Date:  2015-08-04       Impact factor: 22.682

7.  Vascular endothelial growth factor, a novel and highly accurate pancreatic fluid biomarker for serous pancreatic cysts.

Authors:  Michele T Yip-Schneider; Huangbing Wu; Ryan P Dumas; Brad A Hancock; Narasimhan Agaram; Milan Radovich; C Max Schmidt
Journal:  J Am Coll Surg       Date:  2013-12-24       Impact factor: 6.113

8.  Prevalence of unsuspected pancreatic cysts on MDCT.

Authors:  Thomas A Laffan; Karen M Horton; Alison P Klein; Bruce Berlanstein; Stanley S Siegelman; Satomi Kawamoto; Pamela T Johnson; Elliot K Fishman; Ralph H Hruban
Journal:  AJR Am J Roentgenol       Date:  2008-09       Impact factor: 3.959

Review 9.  Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s).

Authors:  Joseph Carmicheal; Asish Patel; Vipin Dalal; Pranita Atri; Amaninder S Dhaliwal; Uwe A Wittel; Mokenge P Malafa; Geoffrey Talmon; Benjamin J Swanson; Shailender Singh; Maneesh Jain; Sukhwinder Kaur; Surinder K Batra
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-10-30       Impact factor: 10.680

10.  Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN.

Authors:  Ying Liu; Sukhwinder Kaur; Ying Huang; Johannes F Fahrmann; Jo Ann Rinaudo; Samir M Hanash; Surinder K Batra; Aatur D Singhi; Randall E Brand; Anirban Maitra; Brian B Haab
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-06-12       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.